Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

IGI reported that it has recently wrapped up the dose-escalation phase of its Phase 1 clinical trial involving patients with ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to attack cancer.

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

Because clinical trials do not mimic the real-world application of multiple myeloma treatments, Ajai Chari, MD, discussed the variety of patient factors clinicians should consider in their practice.

Multiple myeloma (MM) is a complex disease with poor prognosis and its clinical management still remains a challenge in the field. Since both BCMA and GPRC5D are overexpressed in MM cells, a ...